In Vitro Activity of Manogepix (APX001A) and Comparators against Contemporary Molds: MEC Comparison and Preliminary Experience with Colorimetric MIC Determination

Nuclear ribosomal internal transcribed spacer (ITS) region as a universal DNA barcode marker for Fungi

Schoch, C. L., Seifert, K. A., Huhndorf, S. M., Robert, V., Spouge, J. L., Lévesque, C. A., Chen, W., Bolchacova, E., Voigt, K., Crous, P. W., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117018109 · Cited by 5,176 · see citing works

Development of primer sets designed for use with the PCR to amplify conserved genes from filamentous ascomycetes

Glass, N. L., & Donaldson, G. C. (1995) · Applied and Environmental Microbiology · doi:10.1128/aem.61.4.1323-1330.1995 · Cited by 4,765 · see citing works

Internet-Accessible DNA Sequence Database for Identifying Fusaria from Human and Animal Infections

O'Donnell, K. L., Sutton, D. A., Rinaldi, M. G., Sarver, B. A. J., Balajee, S. A., Schroers, H., Summerbell, R. C., Robert, V. A. R. G., Crous, P. W., Zhang, N., et al. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.00989-10 · Cited by 632 · see citing works

EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST)

Arendrup, M. C., Cuenca-Estrella, M., Lass-Flörl, C., & Hope, W. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2012.03880.x · Cited by 451 · see citing works

<i>In Vitro</i> Activity of E1210, a Novel Antifungal, against Clinically Important Yeasts and Molds

Miyazaki, M., Horii, T., Hata, K., Watanabe, N.-A., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., Inoue, S., Matsukura, M., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00291-11 · Cited by 200 · see citing works

Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis

Hata, K., Horii, T., Miyazaki, M., Watanabe, N.-A., Okubo, M., Sonoda, J., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00366-11 · Cited by 149 · see citing works

<i>In Vitro</i> and <i>In Vivo</i> Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris

Hager, C. L., Larkin, E. L., Long, L., Zohra Abidi, F., Shaw, K. J., & Ghannoum, M. A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02319-17 · Cited by 139 · see citing works

Establishing In Vitro-In Vivo Correlations for Aspergillus fumigatus : the Challenge of Azoles versus Echinocandins

Arendrup, M. C., Perkhofer, S., Howard, S. J., García‐Effrón, G., Aimanianda, V., Perlin, D. S., & Lass‐Flörl, C. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00190-08 · Cited by 115 · see citing works

Activities of E1210 and Comparator Agents Tested by CLSI and EUCAST Broth Microdilution Methods against Fusarium and Scedosporium Species Identified Using Molecular Methods

Castanheira, M., Duncanson, F. P., Diekema, D. J., Guarro, J., Jones, R. N., & Pfaller, M. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05414-11 · Cited by 98 · see citing works

Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis

Alkhazraji, S., Gebremariam, T., Alqarihi, A., Gu, Y., Mamouei, Z., Singh, S., Wiederhold, N. P., Shaw, K. J., & Ibrahim, A. S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01735-19 · Cited by 97 · see citing works

How to: EUCAST recommendations on the screening procedure E.Def 10.1 for the detection of azole resistance in Aspergillus fumigatus isolates using four-well azole-containing agar plates

Guinea, J., Verweij, P. E., Meletiadis, J., Mouton, J. W., Barchiesi, F., Arendrup, M. C., Arendrup, M. C., Arıkan-Akdağlı, S., Barchiesi, F., Castanheira, M., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.09.008 · Cited by 91 · see citing works

<i>In Vitro</i> Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017

Pfaller, M. A., Huband, M. D., Flamm, R. K., Bien, P. A., & Castanheira, M. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00840-19 · Cited by 80 · see citing works

In Vitro Activity of a Novel Broad-Spectrum Antifungal, E1210, Tested against Aspergillus spp. Determined by CLSI and EUCAST Broth Microdilution Methods

Pfaller, M. A., Duncanson, F. P., Messer, S. A., Moet, G. J., Jones, R. N., & Castanheira, M. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00570-11 · Cited by 75 · see citing works

Azole-resistant Aspergillus fumigatus in Denmark: a laboratory-based study on resistance mechanisms and genotypes

Jensen, R. H., Hagen, F., Astvad, K. M. T., Tyron, A., Meis, J. F. G. M., & Arendrup, M. C. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.04.001 · Cited by 59 · see citing works

Evaluation of Resistance Development to the Gwt1 Inhibitor Manogepix (APX001A) in Candida Species

Kapoor, M., Moloney, M. K., Soltow, Q. A., Pillar, C. M., & Shaw, K. J. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01387-19 · Cited by 59 · see citing works

Activity of novel antifungal compound APX001A against a large collection of Candida auris

Berkow, E. L., & Lockhart, S. R. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky302 · Cited by 57 · see citing works

In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies

Rivero-Menéndez, O., Cuenca‐Estrella, M., & Alastruey‐Izquierdo, A. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz022 · Cited by 55 · see citing works

APX001A In Vitro Activity against Contemporary Blood Isolates and Candida auris Determined by the EUCAST Reference Method

Arendrup, M. C., Chowdhary, A., Astvad, K. M. T., & Jørgensen, K. M. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01225-18 · Cited by 54 · see citing works

APX001 Pharmacokinetic/Pharmacodynamic Target Determination against Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis

Zhao, M., Lepak, A. J., Marchillo, K., VanHecker, J., Sánchez, H., Ambrose, P. G., & Andes, D. R. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02372-18 · Cited by 51 · see citing works

A multicentre study to optimize echinocandin susceptibility testing of Aspergillus species with the EUCAST methodology and a broth microdilution colorimetric method

Meletiadis, J., Siopi, M., Kanioura, L., Jørgensen, K. M., Perlin, D. S., Mouton, J. W., & Arendrup, M. C. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa102 · Cited by 18 · see citing works

Galactomannan Is a Biomarker of Fosmanogepix (APX001) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis

Gebremariam, T., Alkhazraji, S., Gu, Y., Singh, S., Alqarihi, A., Shaw, K. J., & Ibrahim, A. S. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01966-19 · Cited by 13 · see citing works

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin

Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467 · see citing works

Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections

Shaw, K. J., & Ibrahim, A. S. (2020) · Journal of Fungi · doi:10.3390/jof6040239 · Cited by 229 · see citing works

Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease

Hoenigl, M., Arastehfar, A. A., Arendrup, M. C., Brüggemann, R. J. M., Carvalho, A., Chiller, T. M., Chen, W., Egger, M., Feys, S., Gangneux, J., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00074-23 · Cited by 160 · see citing works

Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective

Lamoth, F., Lewis, R. E., & Kontoyiannis, D. P. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1070 · Cited by 79 · see citing works

Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents

Wiederhold, N. P. (2022) · Journal of Fungi · doi:10.3390/jof8080857 · Cited by 68 · see citing works

Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018–2019)

Pfaller, M. A., Huband, M. D., Flamm, R. K., Bien, P. A., & Castanheira, M. (2021) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2021.04.012 · Cited by 63 · see citing works

Manogepix (APX001A) <i>In Vitro</i> Activity against Candida auris: Head-to-Head Comparison of EUCAST and CLSI MICs

Arendrup, M. C., Chowdhary, A., Jørgensen, K. M., & Meletiadis, J. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00656-20 · Cited by 49 · see citing works

Antifungal Pipeline

McCarty, T. P., & Pappas, P. G. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.732223 · Cited by 47 · see citing works

Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS)

Hodges, M. R., Tawadrous, M., Cornely, O. A., Thompson, G. R., Slavin, M. A., Maertens, J. A., Dadwal, S., Rahav, G., Hazel, S., Almas, M., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf185 · Cited by 43 · see citing works

The antifungal pipeline for invasive fungal diseases: what does the future hold?

Neoh, C. F., Jeong, W., Kong, D. C. M., & Slavin, M. A. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2203383 · Cited by 37 · see citing works

How urgent is the need for new antifungals?

Stewart, A. G., & Paterson, D. L. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1935868 · Cited by 36 · see citing works

In Vitro Antifungal Activity of Manogepix and Other Antifungal Agents against South African Candida auris Isolates from Bloodstream Infections

Maphanga, T. G., Mpembe, R. S., Naicker, S. D., Govender, N. P., & GERMS-SA, F. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01717-21 · Cited by 35 · see citing works

Activities of Manogepix and Comparators against 1,435 Recent Fungal Isolates Collected during an International Surveillance Program (2020)

Pfaller, M. A., Huband, M. D., Rhomberg, P. R., Bien, P. A., & Castanheira, M. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01028-22 · Cited by 34 · see citing works

Investigational Agents for the Treatment of Resistant Yeasts and Molds

Seiler, G. T., & Ostrosky-Zeichner, L. (2021) · Current Fungal Infection Reports · doi:10.1007/s12281-021-00419-5 · Cited by 32 · see citing works

Non-Aspergillus Hyaline Molds: A Host-Based Perspective of Emerging Pathogenic Fungi Causing Sinopulmonary Diseases

Jacobs, S. E., & Walsh, T. J. (2023) · Journal of Fungi · doi:10.3390/jof9020212 · Cited by 13 · see citing works

Antifungal Resistance in Non‐ fumigatus Aspergillus Species

Djènontin, E., Lavergne, R., Morio, F., & Dannaoui, É. (2025) · Mycoses · doi:10.1111/myc.70051 · Cited by 12 · see citing works

Trends of Azole-Resistant Aspergillus Fumigatus Susceptibility Over 12 Years from a German ECMM Excellence Center

Verhasselt, H. L., Thissen, L., Scharmann, U., Dittmer, S., Rath, P., Steinmann, J., & Kirchhoff, L. (2025) · Mycopathologia · doi:10.1007/s11046-025-00941-x · Cited by 10 · see citing works

In vitro activity of novel antifungals, natamycin, and terbinafine against Fusarium

Garbe, E., Ullah, A., Aldejohann, A. M., Kurzai, O., Janevska, S., & Walther, G. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01913-24 · Cited by 10 · see citing works

In Vitro Activity of APX2041, a New Gwt1 Inhibitor, and In Vivo Efficacy of the Prodrug APX2104 against Aspergillus fumigatus

Shaheen, S. K., Juvvadi, P. R., Allen, J., Shwab, E. K., Cole, D., Asfaw, Y. G., Kapoor, M., Shaw, K. J., & Steinbach, W. J. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00682-21 · Cited by 8 · see citing works

The combination of manogepix and itraconazole is synergistic and inhibits the growth of Madurella mycetomatis in vitro but not in vivo

Konings, M., Eadie, K., Strepis, N., Nyuykonge, B., Fahal, A. H., Verbon, A., & van de Sande, W. W. J. (2023) · Medical Mycology · doi:10.1093/mmy/myad118 · Cited by 7 · see citing works

New Perspectives on Antimicrobial Agents: Fosmanogepix

Lamoth, F. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00324-26 · Cited by 3 · see citing works

Novel agents in the treatment of invasive fungal infections in solid organ transplant recipients

Cabrera, N. L., George, I. A., Rauseo, A. M., Mazi, P. B., & Spec, A. (2022) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000995 · Cited by 3 · see citing works

New Antifungal Drugs: Discovery and Therapeutic Potential

Vicente, F., Reyes, F., & Genilloud, O. (2024) · Springer eBooks · doi:10.1007/978-981-99-5696-8_12 · Cited by 3 · see citing works

Novel antifungal compounds against Fusarium spp: A systematic review

de León, N. A., Álvarez‐Villalobos, N. A., Gonzalez, G. H., Treviño‐Rangel, R. D. J., & Montoya, A. M. (2026) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2026.503109 · Cited by 2 · see citing works

Assessment of the molecular identification algorithm and its impact on antifungal susceptibilities against clinical Fusarium isolates: a multicentre study in Taiwan, 2011–2023

Chen, P., Wu, C., Wu, U., Liu, W.-D., & Chen, Y. (2026) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlag022 · Cited by 2 · see citing works

Novel Inositol Acyltransferase (Gwt1) Inhibitor for Fungal Keratitis Treatment: Evaluation of In Vitro and In Vivo Efficacy and Safety

Gowtham, L., Meghana, Y., Mannangatty, T., Vasavi, S., Nirmal, J., Bagga, B., Garg, P., Mishra, D., & Roy, S. (2026) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.67.4.49 · Cited by 2 · see citing works

Manogepix demonstrates potent in vitro activity against Aspergillus, Coccidioides , Scopulariopsis/Microascus, Rasamsonia , and Purpureocillium species, including strains with in vitro resistance to other antifungals

Wiederhold, N. P., Patterson, H. P., Sanders, C. J., & Cañete-Gibas, C. F. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00476-26 · Cited by 2 · see citing works

Wild-type MIC distributions and epidemiological cut-off values for ibrexafungerp, manogepix, and rezafungin against WHO fungal priority pathogens

Morelo, M. J., Firacative, C., García‐Effrón, G., Gómez, B. L., & Ceballos-Garzón, A. (2026) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2026.107870 · Cited by 1 · see citing works

Susceptibility Test Methods: Yeasts and Filamentous Fungi

Johnson, E. M., & Arendrup, M. C. (2023) · ClinMicroNow · doi:10.1002/9781683674849.mcm0135 · Cited by 1 · see citing works

Susceptibility Test Methods: Yeasts and Filamentous Fungi

Johnson, E. M., & Arendrup, M. C. (2023) · ClinMicroNow · doi:10.1002/9781683670438.mcm0135 · Cited by 1 · see citing works

Novel Therapeutic Approaches to Control Fungal Biofilms

Guisso, L. P., Ribeiro, N. P., Carmona, W. R., Roseno, A. C. B., Pessan, J. P., & Monteiro, D. R. (2025) · Springer series on biofilms · doi:10.1007/978-3-031-93315-8_11

Novel antifungal compounds against Fusarium spp: A systematic review

de León, N. A., Álvarez‐Villalobos, N. A., González, G. M., Treviño‐Rangel, R. D. J., & Montoya, A. M. (2026) · Enfermedades infecciosas y microbiologia clinica (English ed ) · doi:10.1016/j.eimce.2026.503109

Performance of the Sensititre YeastOne assay compared with EUCAST E.Def 9.4 against Fusarium clinical isolates: focus on voriconazole and amphotericin B

Chen, P., Wu, U., Liu, W.-D., Huang, Y.-T., & Chen, Y.-C. (2026) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlag181

Manogepix (APX001A) <i>In Vitro</i> Activity against Candida auris: Head-to-Head Comparison of EUCAST and CLSI MICs

Arendrup, M. C., Chowdhary, A., Jørgensen, K. M., & Meletiadis, J. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00656-20 · Cited by 49 · see citing works

Manogepix (APX001A) Displays Potent In Vitro Activity against Human Pathogenic Yeast, but with an Unexpected Correlation to Fluconazole MICs

Arendrup, M. C., & Jørgensen, K. M. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00429-20 · Cited by 37 · see citing works

Activity of manogepix and comparator antifungal agents against uncommon filamentous fungal isolates collected in a global surveillance program

Winkler, M., Klauer, A. L., Edeker, S., Fedler, K. A., Rhomberg, P. R., & Castanheira, M. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.02559-26

In vitro activity of manogepix and comparators against infrequently encountered yeast and mold isolates from the SENTRY Surveillance Program (2017–2022)

Pfaller, M. A., Huband, M. D., Bien, P. A., Carvalhaes, C. G., Klauer, A. L., & Castanheira, M. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01132-23 · Cited by 26 · see citing works

Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018–2019)

Pfaller, M. A., Huband, M. D., Flamm, R. K., Bien, P. A., & Castanheira, M. (2021) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2021.04.012 · Cited by 63 · see citing works